title: The effect of interleukin 36 gene therapy in the regression of tumor.
abstract: BACKGROUND
  Cancer immunotherapy attempts to stimulate the immune system to reject and destroy tumors and is one of the cancer treatment strategies. Recently, interluekin36 (IL36) has been used as immunotherapeutic agents in cancer gene therapy. Present study investigated that the IL36 gene therapy effects on the regression of tumor masses in mouse model. Aim of this study is determination of the gene therapy effects by IL36 in the regression of tumor masses in mouse model.
  
  
  METHODS
  To study the therapeutic efficacy of this cytokine, WEHI-164 tumor cells were transected with mIL36 plasmids. ELISA test was used to check cytokine production by transected cells. To establish fibro sarcoma mouse model, Tumoral transfected cells were injected subcutaneously to inoculate tumor in BALB/C mice. Tumor volumes were measured by caliper. Mice were sacrificed and tumors were extracted. The expression of IL36 and IFN-γ was studied with Real-time PCR and immunoblotting. The expression of Ki-67 (a tumor proliferation marker) in tumor masses was studied by immunohistochemistry staining. In this study we had 2 groups which are treated with IL-36 and Untreated with IL-36 as a blank.
  
  
  RESULTS
  The group treated with IL36 indicated decrease of tumor mass volume (p<0.001). The results of western blotting and real-time PCR showed the IL36 expression increased in the group treated with IL36 (with relative expression of 1.9).
  
  
  CONCLUSIONS
  Immunohistochemistry staining indicated that the Ki-67expression has been reduced in the group interfered with IL36. IL36 gene therapy has therapeutic effects on the regression of tumor masses in fibro sarcoma mouse model.
authors: Dept. of Oral Maxillofacial Surgery, Tehran University of Medical Science, Tehran, Iran.
authors: Shiva
authors: S
authors: Solahaye-Kahnamouii
authors: Dept. of Maxillofacial Surgery, Faculty of Dentistry, Tabriz University of Medical Science, Tabriz, Iran.
authors: Farrokh
authors: F
authors: Farhadi
authors: Dept. of Pediatrics, Nursing and Midwifery Faculty, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Mahni
authors: M
authors: Rahkare-Farshi
authors: Dept. of Oral Medicine, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Farzaneh
authors: F
authors: Pakdel
authors: Dept. of Periodontology, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Atabak
authors: A
authors: Kashefimehr
authors: Dept. of Oral Medicine, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Firouz
authors: F
authors: Pouralibaba
authors: Dept. of Oral Maxillofacial Surgery, Tehran University of Medical Science, Tehran, Iran.
authors: Gholamreza
authors: G
authors: Shirani
authors: Dept. of Oral Maxillofacial Surgery, Tehran University of Medical Science, Tehran, Iran.
authors: Mohammad
authors: M
authors: Bayat
authors: Dept. of Oral Maxillofacial Surgery, Tehran University of Medical Science, Tehran, Iran.
authors: Abbas
authors: A
authors: Karimi
keywords: ELISA; Gene therapy; IL-36; Immunobloting; tumor Mass
references: Methods Mol Biol. 2009;487:303-30
references: 19301654
references: Nat Rev Rheumatol. 2014 Nov;10(11):639-40
references: 25201385
references: Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002225
references: 16034873
references: Clin Dev Immunol. 2010;2010:null
references: 20885915
references: Cancer Gene Ther. 1999 Nov-Dec;6(6):514-22
references: 10608348
references: Gene Ther. 2001 Feb;8(4):332-9
references: 11313808
references: Biomacromolecules. 2009 Jan 12;10(1):41-8
references: 19072631
references: Discov Med. 2013 May;15(84):309-17
references: 23725604
references: Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003 Apr;35(4):311-6
references: 12673383
references: Mol Ther. 2004 Mar;9(3):347-54
references: 15006601
references: J Clin Invest. 2005 Apr;115(4):978-85
references: 15761500
references: Adv Genet. 2005;53PA:1-18
references: 16243058
references: Cancer Gene Ther. 2000 Jan;7(1):83-90
references: 10678360
references: Gene Ther. 2007 Mar;14(6):465-75
references: 17339881
references: J Immunother. 2007 Jul-Aug;30(5):490-8
references: 17589289
references: Curr Gene Ther. 2013 Dec;13(6):421-33
references: 24279313
references: Mol Oncol. 2012 Apr;6(2):242-50
references: 22248437
references: J Exp Med. 1993 Oct 1;178(4):1223-30
references: 8104230
references: J Pharm Pharm Sci. 2011;14(2):181-95
references: 21733408
references: J Control Release. 2010 Mar 3;142(2):245-50
references: 19883708
references: Circulation. 2002 Mar 12;105(10):1233-9
references: 11889019
references: Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2475-80
references: 9482910
references: J Immunol. 2001 Jun 1;166(11):6944-51
references: 11359856
references: Cancer Gene Ther. 2009 Mar;16(3):227-36
references: 18949011
references: Nature. 1999 Oct 7;401(6753):517-8
references: 10524611
references: Gene Ther. 1999 Mar;6(3):338-49
references: 10435084
references: J Surg Oncol. 2004 Jan;85(1):28-35
references: 14696084
references: Ther Deliv. 2013 Oct;4(10):1307-20
references: 24116914
references: Eur J Immunol. 2011 Jun;41(6):1510-5
references: 21618503
references: J Natl Cancer Inst. 1995 Apr 19;87(8):581-6
references: 7538593
references: Acta Biochim Pol. 2003;50(3):613-24
references: 14515144
references: Transgenic Res. 2005 Dec;14(6):877-85
references: 16315093
references: Cancer Res. 2003 Jul 15;63(14):4095-100
references: 12874012
references: Gene Ther. 2008 Aug;15(16):1147-55
references: 18385766
references: Immunotherapy. 2009 Sep;1(5):825-44
references: 20636026
references: Int J Cancer. 2004 Apr 20;109(4):499-506
references: 14991570